AWMF-guideline: Disorders related to cannabis;AWMF-leitlinie: Cannabis-bezogene störungen

Fortschritte der Neurologie Psychiatrie

Volumn 72, Issue 6, 2004, Pages 318-329

  Bonnet, Udo ^a   Harries Hedder, K ^b   Leweke, F M ^c   Schneider, U ^d   Tossmann, P ^e  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Therapiehilfe eV Hamburg ^*  (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e Beratung und Projektentwicklung mbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE; ANANDAMIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; CLONAZEPAM; COCAINE; DIAMORPHINE; DRONABINOL; LORAZEPAM; NABILONE; NEUROLEPTIC AGENT; OPIATE; PSYCHOTROPIC AGENT; RIMONABANT;

ANAMNESIS; ATTENTION DEFICIT DISORDER; CANNABIS ADDICTION; COGNITIVE DEFECT; COMORBIDITY; EVIDENCE BASED MEDICINE; GERMANY; HIPPOCAMPUS; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; INTOXICATION; MOOD DISORDER; NUCLEUS ACCUMBENS; PATIENT CARE; PRACTICE GUIDELINE; PSYCHOSIS; REVIEW; SUBSTANCE ABUSE; SUBSTANTIA NIGRA; SYMPTOM; TREATMENT INDICATION; TREATMENT PLANNING;

CANNABIS; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; MARIJUANA ABUSE; MENTAL DISORDERS; PSYCHOSES, SUBSTANCE-INDUCED; RECURRENCE;

EID: 3042596330     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-818388     Document Type: Review

References (159)

1. Baumann A, Phongsavan P. Epidemiology of substance use in adolescence: prevalence, trends and policy implications. Drug Alcohol Depend 1999; 55: 187-207
2. Kraus L, Augustin R. Repräsentativerhebung zum Gebrauch psychoaktiver Substanzen bei Erwachsenen in Deutschland 2000. München: Institut für Therapieforschung, 2001
3. Gantner A. Cannabis - vom jugendtypischen Konsum zum problematischen Gebrauch. In: Farke W, Graß H, Hurrelmann K (Hrsg). Drogen bei Kindern und Jugendlichen. Stuttgart: Thieme, 2003: 86-93
4. BzgA: Bundeszentrale für gesundheitliche Aufklärung. Die Drogenaffinität Jugendlicher in der Bundesrepublik Deutschland. Köln: 2001
5. Braucht G, Kirby MW, Berry GJ. Psychosocial correlates of empirical types of multiple drug abusers. Journal of Consulting and Clinical Psychology 1978; 46: 1463-1475
6. Tossmann HP, Soellner R, Kleiber D. Cannabis - Konsummuster und Gefährdungspotential. In: Deutsche Hauptstelle gegen die Suchtgefahren (Hrsg.) Jahrbuch Sucht 94. Geesthacht: Neuland, 1993
7. Perkonigg A, Lieb R, Höfler M, Schuster P, Sonntag H, Wittchen H-U. Patterns of cannabis use, abuse and dependence over time: incidence, progression and stability in a sample of 1228 adolescents. Addiction 1999; 94: 1663-1678
8. Kandel DB, Davis M. Progression to regular marijuana involvement: Phenomenology and risk factors for near-daily use. In: Glantz M, Pickens R (eds) Vulnerability to drug abuse. Washington. APA, 1992: 211-253
9. Wittchen H-U, Perkonigg A, Reed V. Comorbidity of mental disorders and substance use disorders. Eur Addict Res 1996; 2: 36-47
10. ElSohly MA. Chemische Bestandteile von Cannabis. In: Grotenhermen F (Hrsg). Cannabis und Cannabinoide. Bern: Huber, 2001: 45-55
11. Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetra- hydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Sol 1971; 93: 217-224
12. Ameri J A. The effects of cannabis on the brain. Prog Neurobiol 1999; 58: 315-348
13. Marzo V Di, Bisogno T, Petrocellis L De. Anandamide: some like it hot. Trends Pharmacol Sci 2001; 22: 346-349
14. Turkanis SA, Cely W, Olsen DM, Karler R. Anticonvulsant properties of cannabidiol. Res Comm Chem Pathol Pharmacol 1974; 8: 231-236
15. Zuardi AW, Guimaraes FS, Guimaraes VMC, Del Bel EA. Cannabidiol. In: Grotenhermen F (Hrsg), Cannabis und Cannabinoide. Bern: Huber, 2001: 383-393
16. Becker S. Cannabiskonsum und Autofahren. Deutsches Ärtzteblatt 1999; 96: A908-909
17. ElSholy MA, Ross SA, Mehmedic Z, Arafat R, Bao Y, Banahan BF. Potency trends of delta-9-THC and other cannabinoids in confiscated marijuana from 1980 to 1997. J Forensic Sci 2000; 45: 24-30
18. Grotenhermen F. Übersicht über die therapeutischen Wirkungen. In: Grotenhermen F (Hrsg). Cannabis und Cannabinoide. Bern: Huber, 2001
19. Erberich H. Neurobiologisch-pharmakologische Grundlagen. In: Kunert HJ (Hrsg). Cannabis. Das unterschätzte Kraut. Aachen: Ariadne-Fach-Verlag, 1999: 83-106
20. Brenneisen R. Pharmakokinetik. In: Grotenhermen F(Hrsg), Cannabis und Cannabinoide. Bern: Huber, 2001: 87-107
21. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91: 1585-1614
22. Aderjan R. Toxikologischer Cannabisnachweis. In: Berghaus G, Krüger H-P (Hrsg). Cannabis im Straßenverkehr. Stuttgart: Fischer, 1998: 153-178
23. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 1990; 13: 420-423
24. Fernandez-Ruiz J, Berrendero F, Hernandez ML, Ramos JA. The endogeneous cannabinoid system and brain development. Trends Neurosci 2000; 23: 14-20
25. Fride E, Barg J, Levy R, Saya D, Heldman E, Mechoulam R, Vogel Z. Low doses of anandamides inhibit pharmacological effects of Δ9- tetrahydrocannabinol. J Pharmacol Exp Therap 1995; 272: 699-707
26. Kreitzer AC, Regehr WG. Retrograde Inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 2001; 29: 717-727
27. Ohno-Shosaku T, Maejima T, Kano M. Endogeneous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001; 29: 729-738
28. Wilson RI, Nicoll RA. Endogeneous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001; 410: 588-592
29. Kim D, Thayer SA. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J Neurosci 2001; 21: RC146
30. 1 opioid receptor mechanism. Science 1997; 276: 2048-2250
31. Ashton C. Pharmacology and effects of cannabis: a brief review. British J Psychiatr 2001; 178: 101-106
32. Ambrosio E, Martin S, Garcia-Lecumberri C, Crespo JA. The neurobiology of cannabinoid dependence: sex differences and potential interactions between cannabinoid and opioid systems. Life Sci 1999; 56: 687-694
33. Chaperon F, Thiebot M-H. Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 1999; 13: 243-281
34. Tanda G, Munzar R, Goldberg SR. Self-administration behaviour is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 2000; 3: 1073-1074
35. Mechoulam R, Parker LA, Gallity R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 2002; 42 (suppl 11): 11S-19S
36. Helou A, Lorenz W, Ollenschläger R, Reinauer H, Schwarz FW. Methodische Standards der Entwicklung evidenz-basierter Leitlinien in Deutschland. Z Ärztl Fortbild Qualitätssich 2000; 94: 330-339
37. American Psychiatric Association (APA). Practice guidelines for the treatment of patients with substance abuse disorders: alcohol, cocaine, opioids. Am J Psychiatr 1995; 152: 111-159
38. SIGN Guidelines. An introduction to SIGN methodology for the development of evidenz-based clinical guidelines, SIGN publication 39. Edinburgh: Scottish Intercollegiate Network 1999 Internet:www.sign.ak.uk
39. Müller W, Lorenz W. Leitlinien der Wissenschaftlichen Medizinischen Fachgesellschaften in der AWMF. In: Lauterbach und Schrappe (Hrsg). Gesundheitsökonomie, Qualitätsmanagement und Evidenz-based Medicine. Schattauer, 2001: 472-478
40. Troisi A, Pasini A, Saracco M, Spalletta G. Psychiatric symptoms in male cannabis users not using other illicit drugs. Addiction 1998; 93: 487-492
41. Kandel D, Chen K. Types of marihuana users by longitudinal course. J Stud Alcohol 2000; 61: 367-378
42. McGee R, Williams S, Poulton R, Moffitt T. A longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addiction 2000; 95: 491-503
43. Swift W, Hall W, Teesson M. Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from a national survey of mental health and wellbeing. Drug Alcohol Depend 2001; 63: 147-153
44. Tashkin DP. Respiratorische Risiken des Marihuanarauchens. In: Grotenhermen F (Hrsg). Cannabis und Cannabinoide. Bern: Huber, 2001: 351-362
45. Taylor DR, Fergusson DM, Milne BJ, Horwood LJ, Moffitt TE, Sears MR, Poulton R. A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults. Addiction 2002; 97: 1055-1061
46. Skopp G, Pösch L, Ganßmann B, Mauden M, Richtwer B, Aderjan R, Mattern R. Freie und glucuronierte Cannabinoide im Urin - Untersuchungen zur Einschätzung des Konsumverhaltens. Rechtsmedizin 1999; 10: 21-28
47. Deutscher Bundestag. Gesetz zur Änderung des Straß enverkehrsgesetzes - vom 28.4.1998. Bundesgesetzblatt 1998; 1/25: 810-811
48. Brenner-Hartmann J. Fahreignungsbeurteilung bei Cannabismißbrauch. In: Berghaus G, Krüger H-P (Hrsg). Cannabis im Straßenverkehr. Stuttgart: Fischer Verlag, 1998: 251-270
49. Manno JE, Ferslew KE, Manno BR. Urine excretion patterns of cannabinoids and the clinical application of EMIT-d.a.u. cannabinoid assay for substance abuse treatment. In: Agurell S, Dewey WL, Willete RE (eds): The cannabinoids: clinical pharmacologic and therapeutic aspects. New York: Academic Press, 1984: 281
50. Huestis MA, Cone EJ. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 1998; 22: 445-454
51. Preston KL, Silverman K, Schuster CR, Cone EJ. Comparison of self-reported drug use with quantitative and qualitative urinanalysis for assessment of drug use in treatment studies. In: Harrison L, Hughes H (Eds). The validity of self-reported drug use: improving the accuracy of survey estimates. NIDA Research Monograph, 1997; 167: 130-145
52. Wied K. Veränderte Missbrauchsmuster und qualifizierte Entzugsbehandlung Jugendlicher. Berlin: Euro-TC-Konferenz, 2002
53. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacol 1999; 141: 385-394
54. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marihuana in humans. Psychopharmacol 1999; 141: 395-404
55. Johns A. Psychiatric effects of cannabis. British J Psychiatr 2001; 178: 116-122
56. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38: 1-20
57. Grant BF, Pickering R. The relationship between cannabis use and DSM-IV cannabis abuse and dependence: Results from the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse 1999; 10: 255-264
58. Swift W, Copeland J, Hall W. Choosing a diagnostic cut-off for cannabis dependence. Addiction 1998; 93: 1681-1692
59. Swift W, Hall W, Didcott P, Reilly D. Patterns and correlates of cannabis dependence among long-term users in an Australian rural area. Addiction 1998; 93: 1149-1160
60. Crowley TJ, Macdonald MJ, Whitmore EA, Mikulich SK. Cannabis dependence, withdrawal, and reinforcement effects among adolescents with conduct symptoms and substance use disorders. Drug Alcohol Depend 1998; 50: 27-37
61. Winters KC, Latimer W, Stinchfield RD. The DSM-IV criteria for adolescent alcohol and cannabis use disorders. J Stud Alcohol 1999; 60: 337-344
62. Nelson CB, Rehm J, Ustun TB, Grant B, Chatterji S. Factor structures for DSM-IV substance disorder criteria endorsed by alcohol, cannabis, cocaine and opiate users: results from the WHO reliability and validity study. Addiction 1999; 94: 843-855
63. Soellner R. Abhängig von Haschisch? Bern: Huber, 2000
64. Lynskey MT, Heath AC, Nelson EC, Bucholz KK, Madden PAF, Slutske WS, Statham DJ, Martin NG. Genetic and environmental contributions to cannabis dependence in a young adult twin sample. Psychol Med 2002; 32: 195-207
65. APA American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington D.C.: 1994
66. Uchtenhagen A. Gegenwärtiger Stand der Haschischforschung. In: Völger, von Welck (Hrsg). Rausch und Realität. Drogen im Kulturvergleich (Bd. 3). Reinbek: Rowohlt, 1982: 1397-1401
67. Wiesbeck GA, Schuckit MA, Kalmijn JA, Tipp JE, Bucholz KK, Smith TL. An evaluation of the history of marijuana withdrawal syndrome in a large population. Addiction 1996; 91: 1469-1478
68. Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999; 94: 1311-1321
69. Heishman SJ, Singleton EG, Liguori A. Marijuana craving questionnaire: development and initial validation of a self-report instrument. Addiction 2001; 96: 1023-1034
70. Kouri EM, Pope HG, Lukas SE. Changes in aggressive behaviour during withdrawal from long-term marijuana use. Psychopharmacol 1999; 8: 483-492
71. Swift W, Hall W. Abhängigkeit. In: Grotenhermen F (Hrsg). Cannabis und Cannabinoide. Bern: Huber, 2001: 283-294
72. Smith NT. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 2002; 97: 621-632
73. Leweke FM, Gerth CW, Klosterkötter J. Cannabis-associated psychosis: epidemiology, pathophysiology and management. CNS Drugs 2003; in press
74. Degenhardt L, Hall W, Lynskey M. Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction 2001; 96: 1603-1614
75. Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatr 2001; 158: 2033-2037
76. Keeler MH, Reifler CB, Liptzin MB. Spontaneous recurrence of marihuana effect. Am J Psychiatr 1968; 125: 140-142
77. Blumenfield M. Flashback phenomena in basic trainees who enter the US Air Force. Military Medicin 1971; 136: 39-41
78. Taeschner K-L. Chronische Cannabiswirkungen, Abhängigkeit, Flashback und Psychosen. In: Berghaus G, Krüger H-P (Hrsg). Cannabis im Straßenverkehr. Stuttgart: Fischer, 1998: 243-250
79. Musty RE, Kaback L. Relationship between motivation and depression in chronic marijuana users. Life Sci 1995; 56: 2151-2158
80. Kunert HJ, Ebel H. Neuropsychologische Auswirkungen der akuten und chronischen Cannabisintoxikation. In: Kunert HJ (Hrsg). Cannabis. Das unterschätzte Kraut. Aachen: Ariadne-Fach-Verlag, 1999: 23-69
81. Curran HV, Brignell C, Fletcher S. Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in frequent cannabis users. Psychopharmacology 2002; 164: 61-70
82. Hart CL, Gorp W van, Haney M, Foltin RW, Fischman MW. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 2001; 25: 757-765
83. Leirer VO, Yesavage JA, Morrow DG. Marijuana carry-over effects on aircraft pilot performance. Aviat Space Environ Med 1991; 62: 221-227
84. Schmidt P, Scheer N, Berghaus G. Cannabiskonsum und Fahrtauglichkeit. Kriminalistik 1995; 49: 241-246
85. Pope HG jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term canabis users. Arch Gen Psychiatry 2001; 56: 909-915
86. Solowji N, Roffman RA, Barbor T, Kadden R, Miller M, Christiansen K, Mc Ree B, Venedetti J. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287: 1123-1131
87. Pope HG jr. Cannabis, cognition, and residual confounding. JAMA 2002; 287: 1172-1174
88. Pope HG jr, Gruber AJ, Yurgelun-Todd D. Residual neuropsychologic effects of cannabis. Curr Psychiatry Res 2001; 3: 507-512
89. Solowij N, Greyner BFS. Langzeiteffekte auf Psyche und Kognition. In: Grotenhermen F (Hrsg). Cannabis und Cannabinoide. Bern: Huber, 2001: 325-338
90. Grella CE, Hser YI, Joshi V, Rouds-Bryant J. Drug treatment outcomes for adolescents with comorbid mental and substance use disorders. J Nerv Ment Disease 2001; 189: 384-392
91. Agosti V, Nunes E, Levin R. Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependance. Am J Drug Alcohol Abuse 2002; 28: 643-652
92. Bobbink AJ, Spohr B. Drogenkonsum und psychische Störungen. Erfahrungen aus der ambulanten Therapie mit Cannabis und Partydrogenmissbrauchern und Abhängigen. In: Bader T (Hrsg). Psychiatrie und Drogensucht. Pabst Verlag, 2002
93. Tossmann HP, Gantner A. Differentielle Aspekte der Haschischabhä ngigkeit. Sucht 1993; 4: 276-281
94. Moggi F. Komorbidität von Angststörungen, Depression oder Persönlichkeitsstörungen und Substanzstörungen. In: Moggi F (Hrsg.). Doppeldiagnosen. Komorbidität psychischer Störungen und Sucht. Bern: Huber, 2002: 65-92
95. Fergusson DM, Horwood J. Early onset cannabis use and psychosocial adjustment in young adults. Addiction 1997; 92: 279-296
96. Fergusson DM, Horwood LJ, Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 2002; 97: 1123-1135
97. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ 2002; 325: 1195-1198
98. Hatzitaskos P, Saldatos CR, Kokkevi A, Stefanis CN. Substance abuse patterns and their association with psychopathology and type of hostility in male patients with borderline and antisocial personality disorder. Compr Psychiatry 1999; 40: 278-282
99. Simons JS, Carey KB. Risk and vulnerability for marijuana use problems: the role of affect dysregulation. Psychol Addict Behav 2002; 16: 72-75
100. Murphy KR, Barkley RA, Bush T. Young adults with attention deficit hyperactivity disorder: subtype differences in comorbidity, educational and clinical history. J Nerv Ment Disord 2002; 190: 147-157
101. Dumas P, Saoud M, Bouafia S. Gutknecht G, Ecochard R, Dalery J, Rochet T, d'Amato T. Cannabis use correlates with schizotypal personality traits in healthy students. Psychiatry Res 2002; 31: 27-35
102. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 26: 1483-1486
103. Os J van, Bak M, Hanssen M, Bijl RV, Graaf R de, Verdoux H. Cannabis use and psychosis: longitudinal population based study. Am J Epidemiol 2002; 156: 319-327
104. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ 2002; 325: 1212-1213
105. Zammit S, Allerbeck P, Andreasson S, Lundberg I, Lewis G. Shelf reported cannabis use as a risk factor for schizophrenia in Swedisch conscripts of 1969: historical cohort study. BMJ 2002; 325: 1-5
106. McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 1995; 15: 277-283
107. Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996; 40: 1155-1163
108. Hambrecht M, Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust NZ J Psychiatry 2000; 34: 468-475
109. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003; 33: 15-21
110. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-279
111. Negrete JC, Knapp WP. The effects of cannabis use on the clinical condition of schizophrenics. NIDA Res Monogr 1996; 67: 321-327
112. Peralta V, Cuesta RW. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand 1992; 85: 127-130
113. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 2002; 252: 86-92
114. Buhler B, Hambrecht M, Loffler W, Heiden W an der, Häfner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002; 54: 243-251
115. Löhrer F. Prognose und Verlauf endogener Psychosen unter Cannabis. In: Kunert HJ (Hrsg.) Cannabis. Das unterschätzte Kraut. Aachen: Ariadne-Fach-Verlag, 1999: 71-106
116. Seifert J, Schlimme J, Wedegärtner F, Emrich HM, Schneider U. Cannabis und Schizophrenie. Sucht 2002; 48: 336-345
117. Alpert JE, Maddocks A, Rosenbaum JF, Fava M. Childhood psychopathology retrospectively assessed among adults with early onset of major depression. J Affect Disord 1994; 31: 165-171
118. Grant BF. Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey of adults. J Subst Abuse 1995; 7: 481-497
119. Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs 1998; 30: 171-177
120. Grinspoon L, Bakalar JB. Marihuana. Die verbotene Medizin. Frankfurt a. M.: Zweitausendundeins, 2000
121. Miller NS, Klamen D, Hoffmann NG, Flaherty JA. Prevalence of depression and alcohol and other of drug dependence in addictions treatment populations. J Psychoactive Drugs 1996; 28: 11-124
122. Rey JM, Sawyer MG, Raphael B, Patton GC, Lynskey M. Mental health teenagers who use cannabis. Results of an Australian survey. Br J Psychiatry 2002; 180: 216-221
123. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 2001; 178: 107-115
124. Gruber AJ, Pope HG, Brown ME. Do patients use marijuana as an antidepressant? Depression 1996; 4: 77-80
125. Stratkowski SM, DelBello MP, Fleck DE, Arndt S. The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry 2000; 48: 477-485
126. Tossmann HP. Ecstasy - Konsummuster, Konsumkontexte und Komplikationen. Ergebnisse der Ecstasy-Infoline. Sucht 1997; 2: 122-131
127. Tossmann HP, Heckmann W. Drogenkonsum Jugendlicher in der Techno-Party-Szene, Ergebnisbericht, Köln: BzgA, 1997
128. Tossmann HP, Boldt S, Tensil M. The use of drugs within the Techno party scene in European metropolitan cities. Eur Addiction Res 2001; 7: 2-23
129. Kleiber D, Soellner R, Tossmann HP, Determinanten unterschiedlicher Konsummuster von Cannabis, Forschungsbericht. Bonn: Bundesministerium für Gesundheit 1995
130. Kandel DB, Faust R. Sequences and stages in patterns of adolescent drug use. Arch Gen Psychiatry 1995; 32: 923-932
131. Fergusson DM, Horwood J. Does cannabis use encourage other forms of illicit drug use? Addiction 2000; 95: 505-520
132. Kleiber D, Kovar K-A. Auswirkungen des Cannabiskonsums. Eine Expertise zu pharmakologischen und psychosozialen Konsequenzen, Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1997
133. Epstein DH, Preston K. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction 2003; 98: 269-279
134. Budney AJ, Bickel WK, Amass L. Marijuana use and treatment outcome among opoid-dependent patients. Addiction 1998; 93: 493-503
135. Grotenhermen F. Übersicht über die unerwünschten Wirkungen von Cannabis und THC. In: Grotenhermen F (Hrsg.). Cannabis und Cannabinoide. Bern: Huber, 2001: 259-274
136. Fergusson DM, Horwood LJ, Northstone K. Maternal use of cannabis and pregnancy outcome. BJOG 2000; 109: 21-27
137. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure: an emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol 2001; 23: 1-11
138. Halikas JA, Weller RA, Morse C, Hoffman RG. Regular marijuana use and its effects on psychosocial variables: a longitudinal study. Compr Psychiatry 1983; 24: 229-235
139. Kandel DB, Davies M, Karus D, Yamaguchi K. The consequences in young adulthood of adolescent drug involvement. Archieves of General Psychiatry 1986; 43: 746-754
140. Hammer T, Vaglum P. Initiation, continuation or discontinuation of cannabis use in the general population. Br J Addiction 1990; 85: 899-909
141. Hammer T. Unemployment and use of drug and alcohol among young people: a longitudinal study in the general population. Br J Addiction 1992; 87: 1571-1581
142. Marcea IT, Kuhlmann T. Leitlinien für die Erbringung medizinischer Leistungen in der Diagnostik, Behandlung und Rehabilitation von Patienten mit Abhängigkeit und/odar schädlichem Gabrauch von psychotropen Substanzen für das Fachgebiat Psychiatrie/Psychotherapie. Suchttherapie 2001; 2: 45-50
143. Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychology 1994; 62: 92-99
144. Stephens RS, Curtin L, Roffman RA. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychology 2000; 68: 898-908
145. Lang E, Engelander M, Brooke T. Report of an integrated brief intervention with a self-defined problem cannabis users. J Subst Abuse Treatment 2000; 19: 111-116
146. Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychology 2000; 68: 1051-1061
147. Hser YI, Grella CE, Hubbard RL, Hsieh S, Fletcher BW, Brown BS, Anglin MD. An evaluation of drug treatment for adolescents in 4 U.S. cities. Arch Gen Psychiatry 2001; 58: 689-695
148. Copeland J, Swift W, Roffman RA, Stephens RS. A randomised controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treatment 2001; 21: 55 - 64
149. Dennis M, Godley SH, Diamond GS, Tims FM, Babor T, Donaldson J, Liddle H, Titus JC, Kaminer Y, Webb C, Hamilton N the CYT steering committee. Main findings of the cannabis youth treatment (CYT) randomized field experiment. 2002 www.chestnut.org/Ll/cyt/findings/index.html
150. Budney AJ, Moore BA. Development and consequences of cannabis dependence. J Clin Pharmacol 2002; 42: 28-33
151. Stephens RS, Babor TF, Kadden R, Miller M, the Marijuana Treatment Project Research Group. The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction 2002; 97 (suppl 1). 109-127
152. Venedetti J, MeRee B, Miller M, Christiansen K, Herrel J, the Marijuana Treatment Project Research Group. Correlates of pre-treatment drop-outs among persons with marijuana dependence. Addiction 2002; 97 (suppl 1): 125-134
153. Haney M, Ward AS, Corner SD, Hart CL, Foltin RW, Fiscman MW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacol 2001; 155: 171-179
154. Haney M, Hart CL, Ward AS, Foltin RW. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacol 2003; 165: 157-165
155. Drogen- und Suchtbericht der Bundesregierung Mai 2002
156. Türk D, Welsch K. EBIS-Jahresstatistik 1999 der ambulanten Beratungs- und Behandlungsstellen für Suchtkranke in Deutschland und SEDOS-Jahresstatistik 1999 der stationären Suchtkrankenhilfe in Deutschland, Sucht 2000; 46: Sonderheft 1
157. Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, Sly K, Devir H, Terry M. Evaluation of a motivational interview for substance use within psychiatric in-patient services. Addiction 2002; 97: 1329-1337
158. Huestis MA, Gorclick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58: 322-328
159. Potvin S, Stip E, Roy J-Y. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol 2003; 18: 121-132